Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

APRI $1.85 0.1700 +10.12%
BPTH $1.20 0.0900 +8.11%
ONCY $0.54 0.0399 +7.98%
PVCT $0.56 0.0300 +5.66%
MEIP $1.77 0.0700 +4.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

LOXO $17.12 -1.0400 -5.73%
GERN $4.15 -0.2500 -5.68%
BLRX $2.50 -0.1500 -5.66%
MNTA $21.27 -1.1600 -5.17%
ENZN $1.21 -0.0600 -4.72%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Intermittent, Low-Carbohydrate Diets More Successful Than Standard Dieting, Present Possible Intervention For Breast Cancer Prevention

(AACR) Dec 8, 2011 - An intermittent, low-carbohydrate diet was superior to a standard, daily calorie-restricted diet for reducing weight and lowering blood levels of insulin, a cancer-promoting hormone, according to recent findings.
read press release 

MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium

(MarketWatch) Dec 7, 2011 - In a 596 patient randomized study, adjunctive use of MarginProbe significantly improved surgical outcomes by improving surgeons' ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by 57%.
read article 

First Genome Sequencing Clinical Trial For Triple Negative Cancer Points to New Treatments

(TGen) Dec 8, 2011 - Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium.
read press release 

Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS

(Generex) Dec 8, 2011 - Generex Biotechnology Corporation today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary, Antigen Express, Inc.
read corporate press release 

Genta Announces Results From Clinical Trial of Tesetaxel as Initial Chemotherapy for Women With Recurrent Breast Cancer

(Yahoo! Finance) Dec 8, 2011 - Genta Incorporated today announced presentation of results from the Company's Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer.
read article 

Exelixis’ Cabozantinib Shows Encouraging Clinical Activity in Patients With Metastatic Breast Cancer

(TheStreet) Dec 7, 2011 - Exelixis, Inc. today reported positive preliminary data from a cohort of 45 patients with metastatic breast cancer (MBC) participating in the ongoing cabozantinib phase 2 randomized discontinuation trial (RDT).
read article 

Ganetespib Shows Clinical Activity in HER2+ and Triple Negative Metastatic Breast Cancer

(Yahoo! Finance) Dec 8, 2011 - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium (SABCS).
read article 

Researchers: Medical Procedure For Breast Cancer Lacks Benefits

(NBC News [Philadelphia, PA]) Dec 7, 2011 - Studies show an increasing surgery among breast cancer patients lacks significant benefits, researchers said at the San Antonio Breast Cancer Symposium earlier today.
read article 

Bilateral Oophorectomy Associated With Higher Prevalence of Low Bone Mineral Density and Arthritis in Younger Women

(AACR) Dec 8, 2011 - Women who underwent surgery to remove their ovaries before the age of 45 years were more likely to have arthritis and low bone mineral density compared with women with intact ovaries, researchers found.
read press release 

MRI May Be Noninvasive Method to Measure Breast Cancer Prognosis

(SABCS) Dec 8, 2011 - Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.
read press release 

Clodronate Appeared Safe, Modestly Affected Breast Cancer Disease Events

(AACR) Dec 7, 2011 - A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the incidence of distant metastases in postmenopausal women.
read press release 

Oral Bisphosphonate Did Not Improve Prognosis for Patients With Breast Cancer

(AACR) Dec 7, 2011 - Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate.
read press release 

Many Women Do Not Undergo Breast Reconstruction After Mastectomy

(AACR) Dec 8, 2011 - Despite the benefits, only a small minority of women, regardless of age, are opting for immediate reconstructive breast surgery after undergoing mastectomy for treatment of breast cancer, according to data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.
read press release 

BRCA Variants Not Tied to Worse Cancer Outcomes

(Reuters) Dec 7, 2011 - The outlook for breast cancer patients carrying variant versions of the BRCA genes is a subject of debate, but a new study suggests those women do just as well as patients with similar cancers, as long as they follow standard treatments.
read article 

Risk For Developing New Cancer in Other Breast Increased For Survivors With BRCA Mutation

(AACR) Dec 8, 2011 - Breast cancer survivors who carry the BRCA1 or BRCA2 genetic mutation are at high risk for developing contralateral breast cancer — a new primary tumor in the other breast — and certain women within this group of carriers are at an even greater risk based on age at diagnosis and first tumor status, according to data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.
read press release 

Hispanic Women May Be More Likely to Die of Breast Cancer Than White Women

(LAT/Booster Shots blog) Dec 7, 2011 - Hispanic women may be at higher risk of dying from breast cancer compared with white women, a study finds.
read article (free registration required) 

Mayo Clinic: Obese Patients With HER2-Positive Breast Cancer May Have Worse Outcomes

(Mayo Clinic) Dec 8, 2011 - Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
read press release 

Obesity Linked to Worse Survival Outcomes in Breast Cancer Adjuvant Therapy

(Baylor College of Medicine) Dec 7, 2011 - Obesity may contribute to worse survival outcomes in early stage breast cancer patients who have received adjuvant therapy to treat their disease, said researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine.
read press release 

Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women With Advanced Breast Cancer

(TheStreet) Dec 7, 2011 - Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 patients with locally recurrent or metastatic estrogen receptor-positive breast cancer, the median overall survival of exemestane plus entinostat patients reached 26.9 months versus 19.8 months for exemestane plus placebo.
read article 

Genentech Announces Positive Results of Pivotal Phase III Study with Pertuzumab in HER2-Positive Metastatic Breast Cancer

(Yahoo! Finance) Dec 7, 2011 - Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.
read article 

New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth

(MarketWatch) Dec 7, 2011 - Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival).
read article 

Why Observing Prostate Cancers Is Gaining Ground On Surgery

(NPR/Shots blog) Dec 7, 2011 - A federally convened panel of experts says most men with newly diagnosed prostate cancer should be offered the chance to put off treatment in favor of medical monitoring of their condition.
read article 

New Setback for Avastin as Breast Cancer Treatment

(NYT/Prescriptions blog) Dec 8, 2011 - Another trial of Avastin as a treatment for metastatic breast cancer has fallen short.
read article 

Hormones and Weight Among Biggest Breast Cancer Risks, Says New Report

(ABC News) Dec 7, 2011 - A new report by the Institute of Medicine found that some environmental exposures play a well-established role in raising breast cancer risk, while others -- such as certain chemicals -- have no impact at all, drawing its conclusions from previous research.
read article 

Big Promise is Seen in 2 New Breast Cancer Drugs

(San Francisco Chronicle/Associated Press) Dec 7, 2011 - Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.
read article